At the J.P. Morgan Healthcare Conference in January 2027, 3DHEALS and Biotools Innovator will co-host an exclusive reception tailored specifically for founders and investors in the biotools sector. While JPM Week traditionally prioritizes therapeutics, this evening offers a dedicated space for the companies building the instruments, platforms, and enabling technologies that power modern biopharma and life science research and development. The gathering is primarily invitation-only for selected founders, investors, and strategic partners, with a limited number of general reception tickets available to the broader biotools community. Designed to foster high-value networking, the event will center on the future of biotools innovation, including but not limited to lab automation, 3D bioprinting, advanced manufacturing, and data-driven discovery.

Stay tuned for the announcement of an exciting in-person event on Jan 10th, 2027.

Subscribe here to get updates.

The post 3HEALS & BioTools Innovator At JPM 2027 🗓 appeared first on 3DHeals.

Why this event? Because future healthcare will be more personalized, 3D data-driven, and digitally fabricated (e.g., 3D printing and bioprinting). Life in 3D is the only niche-focused event that unites the most transformative next-gen medical devices, therapeutics, and biotools under one cohesive investment lens, including but not limited to —cell therapy, biofabrication, frontier medical devices, and drug discovery. If you are ready for a mindset shift, this is the event for you.

Since 2018, 3DHEALS has hosted more than 100 early-stage startups in the 3D medtech and biotech space to raise funds and receive advisory through its Pitch3D program. This year, the company is organizing its first dedicated in-person event for investors and entrepreneurs in this space. The event will take place the night before the official 2026 JP Morgan Healthcare Conference in the beautiful downtown San Francisco office of K&L Gates, California, USA. The goal is to host investors and founders who share a maniacal belief that the 3D mindset will enable the next wave of biomedical innovations.

While this event is mostly by invitation only (for Example, Pitch3D founders), related parties can purchase a limited number of tickets. The event is capped at 150 attendees. To qualify as an investor, you must demonstrate that you are an accredited investor or belong to a relevant investment institution. To qualify for media tickets, you must provide relevant LinkedIn or website credentials to be admitted.

Tentative Agenda:

4:00-4:20 PM Registration/Network

4:20-4:25 PM K&L Gates 3DHEALS Intro

4:25-4:40 PM Keynote Speaker-Mike Cordonnier, CEO, Carlsmed (IPO 2025)

4:40 – 5:40 PM Investor Panel

5:40-6:20 PM Startup Panel 1

6:20-6:30 PM Break

6:30-7:10 PM Startup Panel 2

7:10 – 8:00 PM Networking/Wrap up

4:00 -8:00 Poster Session

Keynote Speaker:

Mike Cordonnier

Mike Cordonnier is the Co-Founder, President and Chief Executive Officer at Carlsmed, and serves as the Chair of the Board of Directors.

With more than two decades of leadership experience introducing groundbreaking medical technologies, Mike has guided teams across both private and public organizations, including NuVasive, Ellipse Technologies, Zimmer Biomet, Orchid Orthopedics, and X-Spine Systems. He holds a Bachelor of Science degree in Mechanical Engineering from the University of Dayton.

Speakers:

Iris Wedeking

Iris Wedeking, MBA, is the CEO and Founder of iDentical, a dental technology company that is revolutionizing tooth replacement with the world’s first drill-free, personalized, 3D-printed dental implants. Mrs. Wedeking has been a visionary leader in the dental industry for 10 years. Prior to founding iDentical, she managed the operations for three dental implant centers in the San Francisco Bay Area, where she saw firsthand the challenges of the current paradigm of implant dentistry for both patients and dentists. This experience inspired her to found iDentical, Inc. to develop and commercialize a drill-free dental implant solution that addresses the drawbacks of traditional dental implants.

Mrs. Wedeking is a two-time founder and CEO. Previously, she founded and scaled a national organization in the oncology sector (Kesem) that is now in its 25th year of operation with 115 chapters across 41 states. She also served as a senior marketing research leader at The Clorox Company. Iris holds an MBA from UC Berkeley’s Haas School of Business and a BA, summa cum laude, from Tufts University. She resides in Walnut Creek, California, with her husband (a dentist) and three children.

Jessica Miller

Jessica Miller is the founder of RocketBio and invests with a long-term, patient-focused approach across tissue engineering, regenerative medicine, and next-generation preclinical tools. Her work centres on advancing breakthrough science into practical clinical and commercial impact.

She serves on the Board of Directors at VoxCell BioInnovation, which develops vascularized 3D-bioprinted tumor models for precision oncology, and is a Director and Strategic Board member at NETRI, a French company creating neuron-based organ-on-chip systems for neurotoxicity, pain, and CNS disease research.

Jessica also supports business development efforts for both companies, forging partnerships across pharma, biotech, and research. With a background in Materials Engineering (University of Toronto) and Nanomaterials (Imperial College London), she brings technical depth and strategic insight to scaling technologies that improve patient outcomes and shape the future of drug development.

Gokce Yildirim

Gilly is a biomedical engineer, inventor, and an operations leader with 20 years of medical device industry and scientific research experience, and currently is the founder and CEO of Vent Creativity Corporation, an AI based digital twin surgical planning and decision-making software serving the orthopaedics and healthcare community.
Gilly started his career in industrial robotic automation, and then translated this knowledge to human biomechanics, design, testing, and regulatory filing of medical devices. Gilly previously advised a multi-billion-dollar industry on product portfolio needs and M&A considerations for multiple $5MM+ NPV projects. He also advised C-level executives for their medical device regulatory and business strategy needs. Gilly has been instrumental in the regulatory testing, documentation, and filing aspects of 13 Class II, 1 IDE, and 1 IND FDA medical device products. Gilly has over 25 peer reviewed published articles in the orthopaedic medical device field. Gilly holds 12 granted patents in the field of big-data driven surgery, additive manufacturing for medical devices, and robotic surgery, and presented foundational research at various peer-reviewed conferences and publications. Gilly holds a Bachelor of Science in Industrial Engineering from NJIT, a Master of Science in Biomedical Engineering and an MBA from Columbia University.

Nikhil S. Joshi

Nikhil Joshi is a Biomedical Engineer with a BS and MS in the field. During undergraduate studies, he was a Research Assistant in Dr. Adam Engler’s lab at UC San Diego, investigating methods to coax stem cells towards various mature cell lineages. Later on, at Columbia University, he served as a Graduate Research Assistant in the lab of Dr. Clark Hung, investigating techniques to enable nutrient delivery to engineered tissue constructs for cartilage cell therapy.

After academia Nikhil has spent 12 years in industry, working as an Engineer and Product Manager on a variety of innovative technologies. Most recently Nikhil was at Auris Health helping to build Monarch, the world’s first robotic endoscopy platform. Nikhil led development of three novel robotic instrumentation devices, from initial concept to design verification testing.

Nikhil has co-invented nine patented technologies, and throughout his career has been driven by the question of how technology can improve healthcare quality.

Karolina Valente

Dr. Karolina Valente is the Founder and CEO of VoxCell, a biotechnology company
advancing 3D bioprinting to develop human-like cancer tissue models and accelerate drug developmnent. With over 12 years of experience in tissue engineering, she holds a Ph.D. in Mechanical Engineering with a focus on bioprinting and drug delivery systems. Under her leadership, VoxCell has grown from 5 to 20 employees and raised over $11M CAD. Her contributions to biotechnology and cancer research have earned her and VoxCell multiple
accolades. In 2023, Douglas Magazine recognized VoxCell as one of its 10 to Watch winners, acknowledging the company’s significant contributions to biotechnology and cancer research. In 2024, Life Sciences BC named VoxCell to its Companies to Watch – Recognition Honour Roll, highlighting its potential and achievements in the life sciences sector. Most recently, The Globe
and Mail’s Report on Business 2025 Changemakers Award recognized Karolina as one of 20 emerging leaders reinventing how business is done in Canada. Passionate about scientific innovation, gender equity, and the future of biotechnology, she continues to drive transformative change in oncology research and 3D bioprinting.

Alyssa Huffman

Alyssa Huffman is an award-winning MedTech entrepreneur, inventor, & thought leader advancing the future of orthopedic & spine care. Orthopedics This Week wrote, “If we were to bet on any young entrepreneur, Alyssa Huffman would be at the top of the list.”

She was the first Commercial Representative appointed to the North American Spine Society (NASS) & has become a respected voice in global spine innovation. Alyssa has presented at the 2025 Congress of Neurological Surgeons Annual Conference, the NASS Biologics Conference, & as both speaker and committee member for the NASS Innovation NetWORK Summit, where she champions evidence-based innovation & commercialization strategy.

In 2009, while working as an Orthopedic/Spine/Biologics Distributor, Alyssa witnessed the devastating complications of failed spine surgery on her diabetic uncle and quadriplegic cousin. This experience inspired the first sketch of what became the A8 INTEGR8™ Porous Pedicle Screw System (the cornerstone of ALLUMIN8’s Therapeutic Hardware™ platform), integrating biomechanical support with regenerative potential to both treat & heal.

Under her leadership, ALLUMIN8 has earned global recognition:
“Best Technology in Spine” Award – Orthopedics This Week
“6 Interesting Orthopedic Startups to Monitor in 2025” – BONEZONE
Global Impact Award 2025 – WashU in St. Louis
$500,000 Awarded – Missouri Technology Corporation
$75,000 Awarded – St. Louis Arch Grants
“Innovators to Watch” – OCCAM Design
“Future Stars of Spine” – Matthew Henshaw
“Top Startups to Watch” – St. Louis Business Journal
“Most Investment Value Award” – MD Inno, Shanghai

Beyond entrepreneurship, Alyssa has contributed to clinical scholarship as co-author of “Innovations in Spine Surgery: A Primer” & “Analgesic Effect of Over-the-Counter Sublingual Magnesium for Trigeminal Neuralgia Management.”

Her two decades of consulting experience span sales, contracting, distribution, marketing, product development, leadership, & team building for MedTech companies across medical devices, biologics, robotics, capital equipment, & pharmaceuticals. Areas of expertise include ortho/spine hardware, regenerative medicine, cardiology, neuro, spine, organ transplant, endovascular therapies, wound healing, temperature management, & stem cell therapies.

Her mission is clear: solve problems for patients, physicians, healthcare organizations, & payors by uniting the healthcare community to create devices, protocols, and techniques that merge rigorous clinical evidence with cost-conscious innovation – accelerating the future of patient care.

Dr. Aadeel Akhtar

Dr. Aadeel Akhtar, CEO and Founder of PSYONIC, started the company after meeting a young girl in Pakistan who was using a tree branch as a prosthetic leg. That moment inspired his mission to create advanced, accessible bionic limbs that restore both function and feeling. PSYONIC’s Ability Hand is the fastest bionic hand on the market, impact-resistant, and the first to provide a sense of touch. It is covered by Medicare and used by humans and robotics companies worldwide, including NASA, Meta, Mercedes, and Google. Dr. Akhtar earned his Ph.D. in Neuroscience and M.S. in Electrical & Computer Engineering from the University of Illinois Urbana-Champaign, and holds a B.S. in Biology and M.S. in Computer Science from Loyola University Chicago. He has been recognized by MIT Technology Review, Newsweek, and secured a three-shark deal on Shark Tank.

Ben Hartkopp

Ben Hartkopp is a seasoned independent researcher, inventor and developer who has been instrumental in co-developing the NovoJet™ Printhead technology since 2016. He is a co-inventor of Quantica’s patent portfolio of printheads, systems and methodologies and currently serves as the Head of Research and IP at Quantica.

Renee Ryan

Renee Ryan is recognized as an industry insider and leading investor, deal-maker, and passionate innovator. She has over 25 years of building category-creating healthcare companies. Renee currently serves as Founder & CEO of PinPrint, a Stanford spin-out focused on optimizing the patient experience for drug and vaccine delivery. She served as CEO and Board member of Cala Health, a pioneer in the field of wearable neuromodulaton therapy having launched two generations of product and consistently doubled revenue each year of her leadership. Previously, she led the medical technology investments for Johnson & Johnson Innovation (JJDC) on the West Coast and Asia Pacific for 8 years. While at J&J, she made over 15 new investments, including the Series A for Cala Health. Other investments include Auris Health, Carbon 3D, Verb Surgical, PowerVision and Tusker Medical, several of which led to significant acquisitions. Previously, she was a healthcare investment banker at Goldman Sachs and Jefferies. She currently sits on the Boards of RefleXion Medical and Neuropace (NPCE).

Mike Graffeo

Mike is the CEO and co-founder of FluidForm Bio, building cures for chronic diseases like type 1 diabetes using 3D bioprinting. In over 25 years in the life sciences, Mike has brought four novel treatments through the FDA that have generated over $20 billion in sales in both startup and growth organizations. Throughout his career, he has worked on the forefront of medicine, translating highly complex treatments and clinical data into successful businesses, in the US and around the world. He is a graduate of Cornell University (B.S. Engineering Physics / Bioengineering, M.Eng. Mechanical Engineering) and Harvard Business School (MBA), where he was a Baker Scholar.

Gurkaran Chowdhry

Gurkaran Chowdhry is a co-founder and the Director of Business Development at 3DBioFibR, where he helps guide the commercial strategy behind the company’s proprietary biomaterials platform. His technical foundation began with graduate research that uncovered key mechanisms behind 3DBioFibR’s fiber formation process, and he is an inventor on the company’s core IP. This mix of scientific depth and business focus allows him to bridge R&D with market needs, support partnership discussions with leading biomedical organizations, and represent the company across industry forums.

In his role, Gurkaran works to align 3DBioFibR’s advanced dry-spinning technology with high-value applications in regenerative medicine, wound care, and surgical materials. The company specializes in manufacturing biopolymer fibers such as collagen, chitosan, and spider silk at a scale far beyond traditional wetspinning or electrospinning methods, enabling the creation of tunable 2D and 3D scaffolds and high-strength yarns for next-generation biomedical products. These materials have been adopted by clinical partners for uses ranging from full thickness wound repair to peripheral nerve regeneration, reflecting the commercial opportunities Gurkaran helps cultivate. His focus on translating technical capability into meaningful partnerships has supported the company’s growing presence in cell biology, tissue engineering, and medical device markets.

Nish Bhat

Nish is the General Partner and Cofounder of Carbon Silicon Ventures, where he invests in companies applying engineering methodologies to biology. He is also a cofounder of the oncology company Color Health.

Jim West

Jim West III is an engineer, entrepreneur, and ecosystem builder working at the intersection of health, business, and technology to accelerate the next generation of life science tools and diagnostics startups. He currently serves as Associate Director at BioTools Innovator, where he helps design and lead programs that connect founders with strategic partners, investors, and expert mentors to bring research-enabling technologies to market faster.

Previously, Jim was co‑founder and CEO of Clara Biotech, where he led the development and commercialization of a patented exosome purification platform and helped position the company for an asset acquisition. Earlier in his career, he contributed to bringing multiple medical devices from concept through prototyping, clinical validation, and FDA clearance, including one of the first mobile medical devices to use an iPhone as a stethoscope. Jim holds master’s degrees in Biomedical Engineering Product Development from the University of Kansas and in Entrepreneurship from Nanyang Technological University in Singapore.

Carlos Ezio

Carlos Ezio is an MIT Innovators 35 Under 35 LATAM honoree and the CEO and co-founder of Criocore, a biotech company developing shelf-stable, human-relevant 3D in vitro models for drug discovery. Criocore’s goal is to provide more predictive and animal-free research tools that improve decision-making in preclinical drug development.

He previously spent six years in the Shrike Zhang Lab, a pioneering group in biofabrication and bioprinting, that is part of Harvard Medical School and Brigham and Women’s Hospital. There, he contributed to more than 30 publications, several patents, and multiple bioprinting systems. Carlos is a mechatronics engineer with expertise spanning 3D bioprinting, cryopreservation, organ-on-chip platforms, and acoustics.

Paul Russo

Paul Russo, is the Founder and CEO of K2X, a unique investment vehicle that will enable the 99% of the world with limited startup experience, to safely invest in this exciting non-correlated asset class – www.k2x.capital – with the expectation of a 2026 NYSE IPO, K2X plans to create “The ETF of Start-ups”. He was the Founder, CEO and Chairman of GEO Semi, a Leading supplier of automotive camera processors acquired by NASDAQ: “INDI”. He sits on several start-up boards and is an advisor to start-ups and VC funds. He was a board member of ATI Technologies through its acquisition by AMD and is active in the Band of Angels. Before GEO, Dr. Russo started Silicon Optix and Genesis Microchip. The latter dominated the chip market for flat computer displays and had a successful NASDAQ IPO in 1998. Prior to the above, he had several senior executive positions at GE. Prior to GE, he was at RCA Laboratories, where he helped develop the world’s first CMOS microprocessor, and the first uses of these devices in video games, auto engine control, and global communications. He has been an active angel investor for over three decades. He received his B. Eng. from McGill and his MSc and PhD in EECS from UC Berkeley. He holds 8 patents, has published extensively, and is the recipient of numerous awards, including the IEEE Centennial Medal and the Tech Pioneer Award from the World Economic Forum.

Event Sponsors:

The post Life in 3D: Investing in the Next Frontier 🗓 appeared first on 3DHeals.

3DHEALS is kicking off its first in-person/hybrid event in 2025 in San Francisco, welcoming investors, entrepreneurs, and innovators in the space. The healthcare industry is transforming, driven by 3D printing and bioprinting technologies redefining patient care. This exclusive in-person event offers an opportunity to explore the latest advancements in custom prosthetics, implants, bioprinted tissues, and scaffolds. Engage with top medical professionals, engineers, and industry pioneers in charge of this rapidly growing sector. For investors, this event is a gateway to high-growth opportunities in healthcare and advanced manufacturing. With global demand for personalized medical solutions rising, 3D printing is set to disrupt traditional supply chains and unlock new revenue streams. Connect with startup founders, industry executives, and R&D leaders driving the commercialization of these technologies. Whether you’re looking to fund the next breakthrough or gain strategic insights into this expanding market, this is an event you won’t want to miss. Secure your place today.

Time/Dates: March 27th, 2025, 5:30 PM – 8:00 PM PST

Location: K&L Gates LLP, 4 Embarcadero Ctr, San Francisco, CA 94111

Agenda:

5:30-6:00 Registration/Networking

6:00-7:20 PM Presentations

7:20-8:00 PM Networking

Apply to speak or sponsor the event: info@3dheals.com

Subscribe here to receive event emails.

Speakers:

Josh Mikulich

Implants & medical technologies sales leader with an emphasis in spinal endoscopy, previously focused on open spine procedures, joint reconstruction, thoracic oncology, and biologics. Currently employed with Arthrex in the spinal endoscopy division. Spinal endoscopy is the most minimally invasive surgical procedure for neural decompression surgery.

Formerly employed with Anatomics as Senior Product Specialist with work involving groundbreaking patient-specific implants mostly for oncology use.

Bhushan Mahadik

Dr. Mahadik received his PhD in Chemical and Biomolecule Engineering at the University of Illinois at Urbana Champaign. His expertise is in the field of tissue engineering, stem cell biology and 3D printing. He was the Assistant Director at the NIH Center for Engineering Complex Tissues (CECT) at the University of Maryland that focused on novel applications of 3D printing and bioreactor technologies. Presently, he is the Director of Research at Prellis Biologics with a focus on using 3D Lymph Node Organoids for the development of new clinically relevant antibodies.

He shares a deep interest in Regenerative Medicine and its applications in the clinical space, ranging from implantable scaffolds for repair and regeneration, to the development and assessment of new therapies using complex in vitro models that recreate native biology.

Rajan Patel

Rajan Patel has over three decades of expertise in driving innovation and advancing commercialization in the healthcare industry. His extensive background encompasses diagnostics, critical care, patient monitoring, and drug delivery technologies. At iO Life Science and iO Life Ventures, he leads the incubation of transformative technologies, overseeing a diverse portfolio of over 20 startups. With significant investment experience and a strong commitment to fostering progress in healthcare, Rajan has played a pivotal role in accelerating the development and commercialization of innovative medical devices. His leadership contributions span renowned companies such as MiniMed, Heartport, Aerogen, M2 Medical, and Cirtec Medical. 

As the CEO of Kallisio, Rajan is at the forefront of advancing patient-specific medical devices, addressing key side effects of cancer therapy, such as oral mucositis and other oncology-related complications. Kallisio is dedicated to driving personalized medicine through innovative solutions that enhance treatment precision and improve patient outcomes. These technologies reflect Kallisio’s broader mission to mitigate the adverse effects of cancer therapy, equipping clinicians with tools to deliver precise, effective, and patient-centered care. 

Kuan-Lin Chen

Dr. Kuan Lin Chen is an orthopaedic surgeon specializing in hip and knee replacement, as well as complex joint reconstruction following musculoskeletal tumor resection. He also serves as a medical advisor at AMED Ventures. With a background in bioengineering from UC Berkeley, he has a strong foundation in medical device design and innovation. In addition to his clinical and advisory roles, he actively lectures at universities on strategic design thinking in medical technology.

A prolific innovator, Dr. Chen holds several patents and made history as the first resident doctor to license technology from his home academic institution to a company. His passion for bridging clinical needs with cutting-edge solutions led him to his advisory role at a Medtech venture group in the Bay Area, where he provides evidence-based analysis to drive investment and development strategies.

Jesse Courtier

Jesse Courtier, is a Healthcare Investor, Entrepreneur, and Pediatric Radiologist. He is current Managing Partner of Healthcare GT Ventures, a new Venture Studio/Venture Platform. He founded Sira Medical, a venture backed UCSF spinout using Augmented Reality for pre-surgical planning and worked to bring this from idea to FDA 510k cleared application. His interests lie in the application of innovative technologies that positively impact patient lives and improve physician workflow efficiency and well-being.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Venue Sponsor:

K&L Gates LLP

The post San Francisco: 3D Printing and Bioprinting for Health 🗓 appeared first on 3DHeals.

Join us for an exciting in-person event at 555 California Street, San Francisco, CA, USA! Discover the latest advancements in 3D technologies for orthopedics. Learn from industry experts, engage in lively discussions, and network with like-minded professionals. This event is a must-attend for anyone interested in the intersection of 3D printing and orthopedics. Don’t miss out on this opportunity to stay at the forefront of innovation in healthcare. The in-person capacity is only 30 people. Registration closes Feb 9th, 2024 for security reasons!

Agenda:
6-6:30 Networking, Food/drinks will be provided
6:30-7:30 Presentations (See speaker info below)
7:30-8:00 Q&A and Networking

Subscribe to get the latest news.

Disclaimer: virtual attendees may have limited ability to interact with the speakers and live audience.

Speakers:

Craig Rosenblum

Craig Rosenblum is the President of Himed. Over 30 years of operation, Himed has become a global leader in calcium phosphate based biomaterial production and has developed proprietary plasma spray coatings and surface treatments. Craig and his team collaborate directly with dental and medical device manufacturers around the world to provide innovative biomaterial solutions. Craig discovered a unique application for MATRIX MCD® post-processing additively manufactured titanium implantable devices using Himed’s proprietary and biocompatible resorbable blast media. Himed has since formed a strategic partnership with Lithoz, a global market leader in 3D printing, to develop new bioceramic bioinks for medical 3D printing. Craig received his B.S. and M.S. degree in Materials Science & Engineering with a Biomaterials concentration from The Johns Hopkins University (Baltimore, MD). With a focus in biomaterials characterization, his groundbreaking research explored the variations in the microstructure and mechanical properties of dental enamel. These studies were the first to demonstrate the unique heterogeneous nature of enamel. Craig currently serves on The Johns Hopkins University Materials Science & Engineering Advisory Board.

Kerim Genc

Kerim serves as a Product Manager for the Simpleware Group at Synopsys, bringing over a decade of expertise to the role. Joining Simpleware in 2011 to oversee regional sales, he seamlessly navigated through progressively influential positions, including global sales and business development, culminating in his current role as a Product Manager. A highly qualified professional, Kerim earned his BS and MS in biomechanics from the University of Calgary and the Pennsylvania State University, respectively. He further solidified his academic credentials with a Ph.D. in Biomedical Engineering from Case Western Reserve University, where he utilized computational methods to investigate innovative countermeasures addressing spaceflight-induced bone loss and fracture risk.

Alyssa Huffman

Alyssa Huffman is the inventor, founder, and CEO of Allumin8. A company dedicated to bringing research-backed innovation to 3D printed orthopedic and spine hardware in an effort to increase implant survivorship and reduce the likelihood of catastrophic revisions. Allumin8’s implants (including the A8 Integr8 Porous Pedicle Screw System – not cleared for sale in the US) are designed to match the trabecular pattern of bone with the intent to study a variety of biologic therapeutics delivered through or drawn into the hardware. No change in surgical technique. No change in care. No change in pricing. Simply providing options that never before existed in hardware for the betterment of the patient. Licensing opportunities are available by contacting alyssa@allumin8.com.

Dean Hughes

Dean Hughes is the Regional Technical Director at Smith and Nephew Orthopedics. He earned his Bachelor’s and Master’s in Mechanical Engineering from the University of Memphis and an MBA from Christian Brothers University. Dean is a registered professional engineer in the State of Tennessee. Dean has designed, developed, and launched over 50 orthopedic implants and instruments projects with Smith and Nephew over the last 22 years. He also holds 15 US patents and several patents that are pending. Dean resides in Memphis with his wife Linda and enjoys restoring classic cars in his ‘spare’ time.

Organizer:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Now on Demand:

Thanks to Our Venue Sponsor:

The post San Francisco: 3D Printing and AI in Orthopedics (In-Person, Hybrid) 🗓 appeared first on 3DHeals.

CELLINK is bringing together key opinion leaders, life science experts, and the brightest minds in bioprinting for a unique event in Portsmouth, UK on 25-27 October. The two-day conference provides attendees with the opportunity to listen to industry leaders explain how they are leveraging bioprinting in their research to tackle research challenges and accelerate discovery. With a mix of sessions, the agenda offers a unique opportunity to learn about the current uses of bioprinting technologies, explore new trends and solutions, gain practical knowledge through interactive workshops, and network with the bioprinting community.

Why should you attend?

• Wide range of scientific sessions: cutting-edge research and advancements shared through data-centric presentations and panel discussions.
• Hear from the pioneers: 10+ key opinion leaders from across the life science arena.
• Experience the latest bioprinting technologies hands-on time with industry-leading bioprinters.
• Join a growing community. Connect with scientists, leaders, and experts, fostering a growing community of collaboration and knowledge sharing in the field of bioprinting.
• Build collaborations and partnerships for future research projects and initiatives.
• Get inspired by the latest breakthroughs and innovative ideas. Learn about techniques, methods, and solutions to take back to your work.

Session topics include 3D cell culture, personalized medicine, drug development, clinical translation, biomaterials, cancer research, alternatives to animal models, tissue engineering, and more.

Event Organizer:

3DHEALS is proud to promote relevant online and in-person events in our communities. Detail here.

The post CELLINK Partnership Conference: A Bioprinting Must-attend Event 🗓 🗺 appeared first on 3DHeals.

This is an invite-only social event focusing on tribal members in healthcare 3D printing, bioprinting, biotech, 3D technologies, and medtech space in NYC. Our premium members, enterprise members, pitch3D companies, and investors will be invited to this event.

Join our memberhips as an individual or company, or our Pitch3D program today!

Subscribe to our email list to #JoinTheTribe

The post #JoinTheTribe Happy Hour: (In-Person) NYC 🗓 🗺 appeared first on 3DHeals.